Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo

Vaccine

Volumn 29, Issue 3, 2011, Pages 558-569

  Powell, Thomas J ^a   Palath, Naveen ^a   DeRome, Mary E ^a   Tang, Jie ^a   Jacobs, Andrea ^a   Boyd, James G ^a  

^a Artificial Cell Technologies Inc   (United States)

Author keywords

Antigen presentation; Nanoparticle; Vaccines

Indexed keywords

CALCIUM CARBONATE; DP 2015 PEPTIDE; DP 2045 PEPTIDE; EPITOPE; GAMMA INTERFERON; NANOCARRIER; OVALBUMIN; PEPTIDE VACCINE; RECOMBINANT OVALBUMIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; AQUEOUS SOLUTION; ARTICLE; ARTIFICIAL BIOFILM; BILAYER MEMBRANE; BIOFILM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LAYER BY LAYER ASSEMBLY; LISTERIA MONOCYTOGENES; LISTERIOSIS; MOUSE; NANOFABRICATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TH2 CELL; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; CALCIUM CARBONATE; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; PHAGOCYTOSIS; T-LYMPHOCYTES;

EID: 78650523335     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.001     Document Type: Article

References (66)

1. Iler R.K. Multilayers of colloidal particles. J Colloid Interface Sci 1966, 21:569-594.
2. Ariga K., Hill J.P., Ji Q. Layer-by-layer assembly as a versatile bottom-up nanofabrication technique for exploratory research and realistic application. Phys Chem Chem Phys 2007, 9(19):2319-2340.
3. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277(5330):1232-1237.
4. Decher G. Polyelectrolyte multilayers, an overview. Multilayer thin films: sequential assembly of nanocomposite materials 2003, 1-46. Wiley-VCH, Weinheim. G.S.J. Decher (Ed.).
5. Lvov Yu M., Sukhorukov G.B. Protein architecture: assembly of ordered films by means of alternated adsorption of oppositely charged macromolecules. Membr Cell Biol 1997, 11(3):277-303.
6. Petrov A.I., Volodkin D.V., Sukhorukov G.B. Protein-calcium carbonate coprecipitation: a tool for protein encapsulation. Biotechnol Prog 2005, 21(3):918-925.
7. Schoeler B., Delorme N., Doench I., Sukhorukov G.B., Fery A., Glinel K. Polyelectrolyte films based on polysaccharides of different conformations: effects on multilayer structure and mechanical properties. Biomacromolecules 2006, 7(6):2065-2071.
8. Zhi Z.L., Liu B., Jones P.M., Pickup J.C. Polysaccharide multilayer nanoencapsulation of insulin-producing beta-cells grown as pseudoislets for potential cellular delivery of insulin. Biomacromolecules 2010, 11(3):610-616.
9. Haynie D.T., Zhang L., Rudra J.S., Zhao W., Zhong Y., Palath N. Polypeptide multilayer films. Biomacromolecules 2005, 6(6):2895-2913.
10. Ai H., Jones S.A., Lvov Y.M. Biomedical applications of electrostatic layer-by-layer nano-assembly of polymers, enzymes, and nanoparticles. Cell Biochem Biophys 2003, 39(1):23-43.
11. Palath N., Bhad S., Montazeri R., Guidry C.A., Haynie D.T. Polypeptide multilayer nanofilm artificial red blood cells. J Biomed Mater Res B: Appl Biomater 2007, 81(1):261-268.
12. Fan Y.F., Wang Y.N., Fan Y.G., Ma J.B. Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption. Int J Pharm 2006, 324(2):158-167.
13. Dai Z., Heilig A., Zastrow H., Donath E., Mohwald H. Novel formulations of vitamins and insulin by nanoengineering of polyelectrolyte multilayers around microcrystals. Chemistry 2004, 10(24):6369-6374.
14. Palankar R., Skirtach A.G., Kreft O., Bedard M., Garstka M., Gould K., et al. Controlled intracellular release of peptides from microcapsules enhances antigen presentation on MHC class I molecules. Small 2009, 5(19):2168-2176.
15. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173(5):3148-3154.
16. Fifis T., Mottram P., Bogdanoska V., Hanley J., Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23(2):258-266.
17. Uto T., Wang X., Akagi T., Zenkyu R., Akashi M., Baba M. Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochem Biophys Res Commun 2009, 379(2):600-604.
18. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 2008, 3(8):e2954.
19. Solbrig C.M., Saucier-Sawyer J.K., Cody V., Saltzman W.M., Hanlon D.J. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 2007, 4(1):47-57.
20. Hamdy S., Elamanchili P., Alshamsan A., Molavi O., Satou T., Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(d,l-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007, 81(3):652-662.
21. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007, 4(1):73-84.
22. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21(11-12):1250-1255.
23. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178(5):2979-2986.
24. Yang Y.W., Hsu P.Y. The effect of poly(d,l-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. Biomaterials 2008, 29(16):2516-2526.
25. Kwon Y.J., Standley S.M., Goh S.L., Frechet J.M. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 2005, 105(3):199-212.
26. Zhi Z.L., Haynie D.T. Straightforward and effective protein encapsulation in polypeptide-based artificial cells. Artif Cells Blood Substit Immobil Biotechnol 2006, 34(2):189-203.
27. Zhong Y., Whittington C.F., Haynie D.T. Stimulated release of small molecules from polyelectrolyte multilayer nanocoatings. Chem Commun (Camb) 2007, 14:1415-1417.
28. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997, 158(6):2723-2730.
29. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
30. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(4):763-775.
31. Gonzalez-Noriega A., Grubb J.H., Talkad V., Sly W.S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980, 85(3):839-852.
32. Kaplan J., Keogh E.A. Analysis of the effect of amines on inhibition of receptor-mediated and fluid-phase pinocytosis in rabbit alveolar macrophages. Cell 1981, 24(3):925-932.
33. Fischer S., Uetz-von Allmen E., Waeckerle-Men Y., Groettrup M., Merkle H.P., Gander B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007, 28(6):994-1004.
34. Waeckerle-Men Y., Scandella E., Uetz-Von Allmen E., Ludewig B., Gillessen S., Merkle H.P., et al. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 2004, 287(1-2):109-124.
35. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300(5625):1524-1525.
36. Agace W., Hedges S., Svanborg C. Lps genotype in the C57 black mouse background and its influence on the interleukin-6 response to E. coli urinary tract infection. Scand J Immunol 1992, 35(5):531-538.
37. Chen W., KuoLee R., Shen H., Busa M., Conlan J.W. Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis. Microb Pathog 2004, 37(4):185-191.
38. Pope C., Kim S.K., Marzo A., Masopust D., Williams K., Jiang J., et al. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol 2001, 166(5):3402-3409.
39. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172(10):6290-6297.
40. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79(15):9694-9701.
41. Harty J.T., Bevan M.J. CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med 1992, 175(6):1531-1538.
42. Harty J.T., Pamer E.G. CD8 T lymphocytes specific for the secreted p60 antigen protect against Listeria monocytogenes infection. J Immunol 1995, 154(9):4642-4650.
43. Kursar M., Kohler A., Kaufmann S.H., Mittrucker H.W. Depletion of CD4+ T cells during immunization with nonviable Listeria monocytogenes causes enhanced CD8+ T cell-mediated protection against listeriosis. J Immunol 2004, 172(5):3167-3172.
44. Minigo G., Scholzen A., Tang C.K., Hanley J.C., Kalkanidis M., Pietersz G.A., et al. Poly-l-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 2007, 25(7):1316-1327.
45. Schmidt W., Buschle M., Zauner W., Kirlappos H., Mechtler K., Trska B., et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 1997, 94(7):3262-3267.
46. Hudecz F. Alteration of immunogenicity and antibody recognition of B-cell epitopes by synthetic branched chain polypeptide carriers with poly[l-lysine] backbone. Biomed Pept Proteins Nucleic Acids 1995, 1(4):213-220.
47. Harrington D.G., Crabbs C.L., Hilmas D.E., Brown J.R., Higbee G.A., Cole F.E., et al. Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid. polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect Immun 1979, 24(1):160-166.
48. Yamamoto A., Kondo S., Kameyama S., Murata R. Studies on adjuvants for human prophylactics. I. Comparison of efficiencies of different adjuvants at various stages of immunization with tetanus and diphtheria toxoids. Jpn J Med Sci Biol 1978, 31(3):263-276.
49. Jiang A., Bloom O., Ono S., Cui W., Unternaehrer J., Jiang S., et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007, 27(4):610-624.
50. Elamanchili P., Lutsiak C.M., Hamdy S., Diwan M., Samuel J. " Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007, 30(4):378-395.
51. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26(13):1626-1637.
52. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004, 304(5673):1014-1018.
53. Blander J.M., Medzhitov R. On regulation of phagosome maturation and antigen presentation. Nat Immunol 2006, 7(10):1029-1035.
54. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440(7085):808-812.
55. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Saltzman W.M., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27(23):3013-3021.
56. Raman S., Machaidze G., Lustig A., Aebi U., Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2006, 2(2):95-102.
57. Schroeder U., Graff A., Buchmeier S., Rigler P., Silvan U., Tropel D., et al. Peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J Mol Biol 2009, 386(5):1368-1381.
58. Pimentel T.A., Yan Z., Jeffers S.A., Holmes K.V., Hodges R.S., Burkhard P. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des 2009, 73(1):53-61.
59. Kaba S.A., Brando C., Guo Q., Mittelholzer C., Raman S., Tropel D., et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009, 183(11):7268-7277.
60. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005, 12(24):1769-1777.
61. Yu S., Feng X., Shu T., Matano T., Hasegawa M., Wang X., et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008, 26(48):6124-6131.
62. Haynie D.T. Physics of polypeptide multilayer films. J Biomed Mater Res B: Appl Biomater 2006, 78(2):243-252.
63. Zheng B., Haynie D.T., Zhong H., Sabnis K., Surpuriya V., Pargaonkar N., et al. Design of peptides for thin films, coatings and microcapsules for applications in biotechnology. J Biomater Sci Polym Ed 2005, 16(3):285-299.
64. Chong S.F., Sexton A., De Rose R., Kent S.J., Zelikin A.N., Caruso F. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 2009, 30(28):5178-5186.
65. Sexton A., Whitney P.G., Chong S.F., Zelikin A.N., Johnston A.P., De Rose R., et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 2009, 3(11):3391-3400.
66. De Koker S., Naessens T., De Geest B.G., Bogaert P., Demeester J., De Smedt S., et al. Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. J Immunol 2010, 184(1):203-211.